Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Good find money! The article notes “Hevolution also has a North American centre and an annual budget of up to $1 billion.”
Good thing Genflow have launched on OTC and their new marketing team Harbor Access are Toronto based. Would be good to see the company also eligible for such grants :)
Nice to see our investment tick up passively over the course of the month under radar.
Looking forward to when the team do their FDA submission, have further updates on the new programmes, feedback on the 2 patents (and maybe more), and receipt of the non dilutive grants!
"According to a Deloitte report, the 50 biggest longevity companies raised more than $1 billion in venture capital funding as of 2020 — a number that the company said would rise “due to the growing conviction that the longevity market could outstrip the existing health care market.” Altos Labs, a “rejuvenation” biotech whose investors include Jeff Bezos, announced in 2022 that it had raised $3 billion in funding."
https://www.vox.com/the-highlight/24121932/anti-aging-longevity-science-health-drugs
Money, if you get access to the document, it shows last month 2 of the non dilutive grant tranches were received totalling approx €1.1m. I’m assuming that it’s so buried in the annual report, that the market won’t yet catch on, so if they reinstate us, with the recent dilution, it’s a great opportunity for us to fill our boots as cash runway is covered for the next 12 months.
I have just under 1% of the company float, so dare not dream about a buy out. I know the directors would not consider any petty sums for a takeover, especially with their current cash position, ability to attract European Union backed non dilutive grants, 2 patents pending, 4 core programmes in development, overarching protection from other awarded patents and billion dollar deals being agreed for early stage pharma companies.
I’m going to try remain hopeful but realistic that it’s just a due diligence exercise and good conduct on behalf of the company, or I might make myself sick with shock.
This article today alone, shows anything biopharma is hot stuff, with companies being snapped up for £billions.
https://www.biospace.com/article/biospace-mergers-and-acquisitions-tracker/
Would be nice to see some juicy news from Eric and the team, especially following todays bumper bonanza!
He did say Q2 was when he expected things to get moving, so I’m expecting a news fresh period :)